Section one: Contracting authority
one.1) Name and addresses
MEDICINES DISCOVERY CATAPULT SERVICES LIMITED
Block 35g Mereside,Alderley Park
MACCLESFIELD
SK10 4ZF
procurement@md.catapult.org.uk
Country
United Kingdom
NUTS code
UKD62 - Cheshire East
Companies House
09928547
Internet address(es)
Main address
one.4) Type of the contracting authority
Other type
Drug Discovery / Health
one.5) Main activity
Other activity
Drug Discovery / Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
A multi-drug resistant pathogen reference strain and clinical isolate collection
two.1.2) Main CPV code
- 73200000 - Research and development consultancy services
two.1.3) Type of contract
Services
two.1.4) Short description
A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.
Continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £695,718
two.2) Description
two.2.2) Additional CPV code(s)
- 73200000 - Research and development consultancy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The UKHSA are well positioned to provide the services required by PACE for PACE portfolio funded projects and the wider AMR community. This will include but not be limited to the following:
AST against a well characterised (including phenotypically, whole-genome sequenced with full antibiogram data) set of isolates and strains directly relevant to the PACE funding call, and;
AST data delivered according to industry standards, and;
Provided in an open-access environment, enabling PACE awardees to directly learn from and access the lab capability provided for onward studies, and;
An opportunity to transfer specific isolates to PACE awardee labs for onward studies, and;
The isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally, and;
UKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing, and;
A service model that can account for diverse needs of the PACE-funded projects as they arise i.e. variations to SOPs as required and ability to provide rapid surge capacity as and when needed.
two.2.5) Award criteria
Price
two.2.11) Information about options
Options: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the cases listed below
- The procurement falls outside the scope of application of the regulations
Explanation:
Following the voluntary ex ante transparency (VEAT) notice previously published, indicating that Medicines Discovery Catapult, intends to enter into a contract with the UK Health Security Agency (UKHSA) for a multi-drug resistant pathogen reference strain and clinical isolate collection without a call to competition in accordance with the Public Contracts Regulations 2015 ((32.2(b) ii), Medicines Discovery Catapult has now entered into the contract with UKHSA.
The contract is directly aligned to the PACE (Pathways to Antimicrobial Clinical Efficacy) first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression and will allow continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus.
This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.
The UKHSA maintains unique capabilities and assets that are part of the country's critical national infrastructure to support this aim, this includes;
The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR), which identifies emergence and trends in key resistance-causing pathogens.
The AMRHAI (antimicrobial resistance and healthcare associated infections) national reference unit, part of the Bacteriology reference department (BRD) - a national and international laboratory reference centre for a bacterial infections.
The isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally and;
UKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.1) Previous publication concerning this procedure
Notice number: 2023/S 000-036804
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
2 January 2024
five.2.2) Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
UK Health Security Agency
Salisbury
Country
United Kingdom
NUTS code
- UK - United Kingdom
Justification for not providing organisation identifier
Not on any register
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £695,718
Total value of the contract/lot: £695,718
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
Medicines Discovery Catapult
Macclesfield
SK10 4ZF
Country
United Kingdom